Sexcord/ stromal ovarian tumors laboratory findings

Jump to navigation Jump to search

Sexcord/ stromal ovarian tumors Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sexcord/ stromal ovarian tumors laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sexcord/ stromal ovarian tumors laboratory findings

CDC on Sexcord/ stromal ovarian tumors laboratory findings

Sexcord/ stromal ovarian tumors laboratory findings in the news

Blogs on Sexcord/ stromal ovarian tumors laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Sexcord/ stromal ovarian tumors laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  ; Maneesha Nandimandalam, M.B.B.S.[2]

Overview

Laboratory findings consistent with the diagnosis of sexcord/ stromal ovarian tumors include identifying the presence or absence of tumor markers like AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; E2: estradiol; hCG: human chorionic gonadotropin; LDH: lactate dehydrogenase; testost: testosterone; andro: androstenedione; DHEA: dehydroepiandrostenedione;

Laboratory Findings

Sex cord-stromal tumors AFP hCG LDH E2 Inhibin Testosterone Androstenedione DHEA AMH
Thecoma-fibroma - - - - - - - - -
Granulosa cell tumors - - - +/- + +/- - - +
Sertoli-Leydig tumors +/- - - +/- +/- +/- +/- +/- -

AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; E2: estradiol; hCG: human chorionic gonadotropin; LDH: lactate dehydrogenase; testost: testosterone; andro: androstenedione; DHEA: dehydroepiandrostenedione; .

References

  1. ↑ Rey RA, Lhommé C, Marcillac I, Lahlou N, Duvillard P, Josso N, Bidart JM (March 1996). "Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol". Am. J. Obstet. Gynecol. 174 (3): 958–65. PMID 8633676.
  2. ↑ Robertson DM, Cahir N, Burger HG, Mamers P, Groome N (March 1999). "Inhibin forms in serum from postmenopausal women with ovarian cancers". Clin. Endocrinol. (Oxf). 50 (3): 381–6. PMID 10435065.
  3. ↑ Robertson DM, Stephenson T, Pruysers E, Burger HG, McCloud P, Tsigos A, Groome N, Mamers P, McNeilage J, Jobling T, Healy D (May 2002). "Inhibins/activins as diagnostic markers for ovarian cancer". Mol. Cell. Endocrinol. 191 (1): 97–103. PMID 12044923.
  4. ↑ Markova D, Milchev N, Batashki I, Uchikov A (2008). "[Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women]". Akush Ginekol (Sofiia) (in Bulgarian). 47 (1): 16–9. PMID 18642569.
  5. ↑ Robertson DM, Stephenson T, Pruysers E, McCloud P, Tsigos A, Groome N, Mamers P, Burger HG (February 2002). "Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer". J. Clin. Endocrinol. Metab. 87 (2): 816–24. doi:10.1210/jcem.87.2.8198. PMID 11836327.
  6. ↑ Kurihara S, Hirakawa T, Amada S, Ariyoshi K, Nakano H (December 2004). "Inhibin-producing ovarian granulosa cell tumor as a cause of secondary amenorrhea: case report and review of the literature". J. Obstet. Gynaecol. Res. 30 (6): 439–43. doi:10.1111/j.1447-0756.2004.00231.x. PMID 15566459.
  7. ↑ Ran S, Yu Q, Deng S, Xu L (April 2017). "Luteinizing hormone elevation in ovarian granulosa cell tumor: a case report and review of the literature". J Ovarian Res. 10 (1): 30. doi:10.1186/s13048-017-0327-2. PMC 5404692. PMID 28438188.
  8. ↑ Bufa A, Farkas N, Preisz Z, Poór V, Páger C, Szukits S, Farkas B, Gőcze PM (June 2017). "Diagnostic relevance of urinary steroid profiles on ovarian granulosa cell tumors: two case reports". J Med Case Rep. 11 (1): 166. doi:10.1186/s13256-017-1324-1. PMC 5480180. PMID 28637499.

Template:WH Template:WS